Navigation Links
ATL/TV1102 Trial Results Presented at World Congress on Treatment and Research in Multiple Sclerosis
Date:9/21/2008

- Conference call webcast Monday, 5:00 p.m. EDT and Tuesday, 7:00 a.m. Australian EST at http://www.antisense.com.au and http://www.isispharm.com

MELBOURNE, Australia and CARLSBAD, Calif., Sept. 22 /PRNewswire-FirstCall/ -- Antisense Therapeutics Ltd. (ASX: ANP) and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) are pleased to advise that the results from the ATL/TV1102 Phase IIa clinical trial in patients with multiple sclerosis (MS) were presented Saturday at the World Congress on Treatment and Research in Multiple Sclerosis in Montreal, Canada by the Principal Investigator for the trial, Volker Limmroth, M.D., Ph.D., Chairman of the Department of Neurology, Cologne City Hospitals, Germany.

As previously reported, ATL/TV1102 significantly reduced disease activity in patients with Relapsing Remitting Multiple Sclerosis (RRMS) in a randomized, double-blind, placebo-controlled Phase II study designed to obtain evidence of ATL/TV1102's effectiveness in reducing MS-related brain lesions as detected by magnetic resonance images (MRI). The study met its primary endpoint showing a significant reduction by 54.4% (p=0.01) in cumulative number of new active lesions in the ATL/TV1102 treated patients compared to placebo. Further details on the study design and outcomes are provided in the conference abstract which follows this document.

Dr. Limmroth said, "As VLA-4 is a clinically validated target in MS, there is high interest in the potential application of treatment modalities directed against this target. In our study we were able to demonstrate, for the first time, that a second-generation antisense drug designed to speci
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.; Antisense Therapeutics Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)...  Halozyme Therapeutics, Inc. (NASDAQ: HALO ... Drug Administration (FDA) has removed the clinical hold ... SWOG,s ongoing Phase 1b/2 clinical trial (S1313). The ... PEGPH20 (PEGylated Recombinant Human Hyaluronidase) in combination with ... pancreatic adenocarcinoma.  The study will resume under a ...
(Date:9/18/2014)... 2014 Australian biomarker discovery company Minomic International ... its MiStat™ prostate cancer screening test, planning to achieve ... completion. Minomic,s proprietary MiStat™ technology is a ... proprietary biomarker known as the MIL-38 antigen. This biomarker ... Researchers at 11 leading urology centres ...
(Date:9/18/2014)... , Sept. 18, 2014 /CNW/ - A new expert ... Canada , released today by the ... safe and effective medicines for children. Each year about ... children use at least one prescription drug. Much of ... from the authorized use), creating potential health risks. ...
Breaking Medicine Technology:SWOG To Resume Clinical Trial Of Halozyme's PEGPH20 In Combination With Modified FOLFIRINOX For Advanced Pancreatic Cancer 2SWOG To Resume Clinical Trial Of Halozyme's PEGPH20 In Combination With Modified FOLFIRINOX For Advanced Pancreatic Cancer 3SWOG To Resume Clinical Trial Of Halozyme's PEGPH20 In Combination With Modified FOLFIRINOX For Advanced Pancreatic Cancer 4Minomic Launches US Pilot Study of MiStat(TM) Novel Prostate Cancer Screening Technology 2Studying medicines in children is always possible and is in their best interest, finds Expert Panel 2Studying medicines in children is always possible and is in their best interest, finds Expert Panel 3
... 17, 2011 Pharmatek Laboratories, Inc., a premier ... industry, announced that it has been approved by ... the analysis of Schedules I through V controlled ... manufacture drug products containing Schedules IV and V ...
... 2011 The U.S. Food and Drug Administration today ... with methotrexate, for the treatment of active systemic ... years and older. (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ... a rare, potentially life-threatening disorder in children that ...
Cached Medicine Technology:Pharmatek Granted Approval by the DEA for Analysis of All Controlled Substances 2FDA Approves Actemra to Treat Rare Form of Juvenile Arthritis 2FDA Approves Actemra to Treat Rare Form of Juvenile Arthritis 3
(Date:9/18/2014)... Clinical trial report, “Edema Global Clinical Trials ... trial scenario. This report provides elemental information and data ... an overview of the trial numbers and their recruitment ... the globe. The databook offers a preliminary coverage of ... of the sponsors and also provides briefing pertaining to ...
(Date:9/18/2014)... This past August, Narconon Louisiana New Life ... the kissing booth during the West Feliciana Animal Humane Society fundraiser ... have loved animals my whole life and have always had animals ... strays who needed a home. Supporting an animal shelter allows ... all home!” , The CEO of Narconon Louisiana was there not ...
(Date:9/18/2014)... (PRWEB) September 18, 2014 Relias Learning, the ... and human services markets, today announced it has been named ... growing private companies in America. , In the three-year period ... moved up almost 2,000 spots on the Inc. 5000 list ... , “The industries we serve continue to grow, ...
(Date:9/18/2014)... The new BuildClean™ Dust Control ... and homeowners alike as it eliminates the top ... causes potential health issues, and makes it “unlivable” ... system allows contractors to virtually eliminate airborne dust ... remodeling tasks. , BuildClean removes up to 90 ...
(Date:9/18/2014)... Salamon HealthDay Reporter ... midlife may be associated with increased odds of developing ... new research suggests. The study, which did not ... also suggested that the migraine-Parkinson,s association was stronger in ... a warning sign of a pending attack that includes ...
Breaking Medicine News(10 mins):Health News:Edema Therapeutics Clinical Trials Market 2014 Review Report Available at MarketOptimizer.org 2Health News:Edema Therapeutics Clinical Trials Market 2014 Review Report Available at MarketOptimizer.org 3Health News:Edema Therapeutics Clinical Trials Market 2014 Review Report Available at MarketOptimizer.org 4Health News:Narconon New Life Retreat Supports Local Animal Shelter At Recent Fundraiser 2Health News:Relias Learning Named to Inc. 5000 List for Second Consecutive Year 2Health News:New BuildClean™ System Brings Livability Back to Home Remodeling 2Health News:New BuildClean™ System Brings Livability Back to Home Remodeling 3Health News:New BuildClean™ System Brings Livability Back to Home Remodeling 4Health News:Are Migraines in Middle Age Tied to Raised Parkinson's Risk Later? 2Health News:Are Migraines in Middle Age Tied to Raised Parkinson's Risk Later? 3
... a newborn baby going under the knife to repair a ... work begins for parents. University of Alberta nursing professor Gwen ... a former pediatric cardiology nurse; she wanted to find out ... per cent convinced that health-care professionals get what these parents ...
... 26 The Providence Service,Corporation (Nasdaq: PRSC ) ... financial advisor. , In ... strategic,options relating to, among other things, delevering its debt, growing ... UBS,Investment Bank has been retained in connection with selling certain,non-strategic ...
... Stylists, beauticians may be affected by phthalates in these ... -- Mothers exposed to a common hairspray chemical while ... born with an abnormally placed urinary opening, a new ... fragrances, and nail and hair products contain chemicals called ...
... are misaligned and point outward are at significantly ... adulthood, according to findings of a Mayo Clinic ... ( http://pediatrics.aappublications.org/cgi/content/full/122/5/1033 ), the official journal of the ... examined the medical records of 407 patients with ...
... it,s cheaper and less time-consuming than in-person visits, study ... counseling may be as effective as face-to-face counseling in ... University of Florida study included 234 obese women, ages ... Florida. , All the women completed a six-month weight-loss ...
... Public engagement practitioners from across the world are to ... be held in South Africa, organised by the Wellcome ... engage to empower" will take place from 2-5 ... Studies, KwaZulu-Natal. It will bring together practitioners working in ...
Cached Medicine News:Health News:Parents are the unsung heroes 2Health News:Providence Service Corporation Retains UBS Investment Bank as its Financial Advisor in Connection With the Sale of Certain Non-Strategic Assets 2Health News:Over-the-Phone Weight Loss Counseling Works 2Health News:International workshop aims to boost public engagement work in developing countries 2Health News:International workshop aims to boost public engagement work in developing countries 3
... two-piece Titanium (Ti-6Al-4V) screw offered in two ... of lengths. The two pieces are loaded ... A single instrument set contains all items ... Standard and Mini Kompressor Compression Screws. , ...
... The cornerstones of the Acutrak family ... Screw Systems. Together they are used primarily ... of the upper extremity, but have been ... The bones stabilized with these two systems ...
... combined with the IRIS Medical OcuLight ... consoles,the EasyView slit lamp adapter (SLA) ... laser photocoagulation,to your existing Haag-Streit slit ... and glaucoma,without compromising the diagnostic functions ...
... revolutionized the wrist arthroplasty market with the ... We're at it again, with the release ... Like the original, the Universal2 System continues ... debilitating arthritis. To date, we now have ...
Medicine Products: